Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology

Rob Hill^{1,2 *} and Meritxell Canals^{1,2 *}

¹*Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom*

²*Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Midlands, United Kingdom.*

* Correspondence: rob.hill@nottingham.ac.uk and m.canals@nottingham.ac.uk

Abstract

Morphine and other mu-opioid receptor (MOR) agonists remain the mainstay treatment of acute and prolonged pain states worldwide. The major limiting factor for continued use of these current opioids is the high incidence of side effects that result in loss of life and loss of quality of life. The development of novel opioids bereft, or much less potent, at inducing these side effects remains an intensive area of research, with multiple pharmacological strategies being explored. However, as with many G protein-coupled receptors (GPCRs), translation of promising candidates from in vitro characterisation to successful clinical candidates still represents a major challenge and attrition point. This review summarises the preclinical animal models used to evaluate the key opioid-induced behaviours of antinociception, respiratory depression, constipation and opioid-induced hyperalgesia and tolerance. We highlight the influence of distinct variables in the experimental protocols, as well as the potential implications for differences in receptor reserve in each system. Finally, we discuss how methods to assess opioid action in vivo and in vitro relate to each other in the context of bridging the translational gap in opioid drug discovery.

Keywords: opioids, antinociception, respiratory depression, constipation, opioid-induced hyperalgesia, tolerance

Table of Contents

1. Introduction
2. Assessment of opioid-induced antinociception
3. Assessment of opioid-induced respiratory depression
4. Assessment of opioid-induced constipation
5. Assessment of opioid-induced hyperalgesia and antinociceptive tolerance
6. In vitro measurements of opioid pharmacology and their relationship with opioid-induced effects in vivo
7. Concluding remarks
8. References

Abbreviations:

GPCR G protein-coupled receptor

MOR mu-opioid receptor

OIH opioid-induced hyperalgesia

OIC opioid-induced constipation

WBP whole body plethysmography

1- Introduction

Opioids are the gold standard for analgesic medications, both for acute severe pain and chronic pain management. Chronic pain in particular is a major health issue across the world today. Estimates of the prevalence of chronic pain range from 20 to 40% of the population in both developing (Sá, et al., 2019) and developed (Dahlhamer, et al., 2018) countries, representing a significant societal and economic cost.

Opioids still remain mainstay analgesics despite the suite of on-target side effects mediated by activation of the μ -opioid receptor (MOR), the primary target of most opioid pain medications (Matthes, et al., 1996). Two major side effects include respiratory depression and addiction. These side effects are, in many ways, the “face” of opioids (Okie, 2010), with respiratory depression being the cause of fatality in an overdose situation and opioid addiction being present in most, if not all, countries worldwide. In 2017, fatal opioid overdoses totalled over 60,000 in the USA (Hedegaard H, 2017) and the number and rate of increase in overdose deaths was the highest in the UK since records began (Office of National Statistics, 2019). Additional side effects include constipation, due to opioid-induced reduction in gut motility, and hyperalgesia, a condition where opioid use paradoxically induces a heightened sensitivity to pain (Benyamin, et al., 2008). These are still significant side effects that affect the quality of life and decrease patient compliance (Camilleri, 2011; Katz, 2002; Panchal, Mueller-Schwefe, & Wurzelmann, 2007).

Intense research is currently addressing the urgent need for improved and safer analgesics, either through the discovery and validation of new targets such as other cell surface receptors e.g. cannabinoid receptors (Vučković, Srebro, Vujović, Vučetić, & Prostran, 2018), voltage-gated sodium channels (Bennett, Clark, Huang, Waxman, & Dib-Hajj, 2019), targeted toxins (Yaksh, Woller, Ramachandran, & Sorkin, 2015) or through the development of new opioid receptor ligands with new mechanisms of action (Crombie, et al., 2015; Dekan, et al., 2019; DeWire, et al., 2013; Gassaway, Rives, Kruegel, Javitch, & Sames, 2014; Koblish, et al., 2017; Schmid, et al., 2017).

Early data from arrestin-3 KO mice suggested that with the removal of arrestin-3 morphine induced enhanced antinociception, with a reduced degree of respiratory depression (Raehal, Walker, & Bohn, 2005). Since then, focus has been centred in the development of G protein-biased agonists to potentially retain the antinociceptive properties while avoiding the respiratory depressant effects (Dekan, et al., 2019; DeWire, et al., 2013; Gillis, Gondin, et al., 2020; Manglik, et al., 2016; Schmid, et al., 2017; Varadi, et al., 2016). Some novel opioids generated based on this hypothesis have resulted in marginally improved separation between the antinociceptive and respiratory depressant dose response curves (DeWire, et al., 2013; Gillis, Gondin, et al., 2020; Schmid, et al., 2017). However, the mechanisms responsible for this wider therapeutic windows are still unclear (Azevedo Neto, et al., 2020; Bachmutsky, Durand, et al., 2020; Haouzi, et al., 2021; Kliewer, et al., 2020; Kliewer, et al., 2019).

Other strategies to develop improved opioid analgesics target other opioid receptor subtypes. κ -Opioid receptor (KOR) agonists have been shown to provide effective antinociception without inducing respiratory depression. However, the dysphoria associated with KOR agonism limits their clinical utility (Chavkin & Koob, 2016). Several reports suggest that dysphoria is induced predominantly by activation of an arrestin-mediated signalling pathway (Brust, et al., 2017; Lovell, et al., 2017) suggesting the development of G-protein biased KOR agonists as a potential strategy to develop new analgesics. Unfortunately, attempts to obviate KOR-induced dysphoria whilst producing an appreciable level of antinociception have not translated into therapies as yet (Mores, Cummins, Cassell, & van Rijn, 2019). There has also been an increasing body of evidence suggesting that the δ -opioid receptor (DOR) may be an attractive target for specific modalities of pain such as chronic inflammatory or neuropathic pain (A. A. Pradhan, Befort, Nozaki, Gavériaux-Ruff, & Kieffer, 2011). However, interest in DOR therapeutics has been limited due to pro-convulsive activity exhibited by certain DOR agonists (Broom, et al., 2002), as well as an apparent greater liability for tolerance (A. A. Pradhan, et al., 2010). Attempts to alleviate these side effects are ongoing (Audet, et al., 2012; Charfi, Audet, Bagheri Tudashki, & Pineyro, 2015; Alexandra E. Conibear, et al., 2020). Additionally, beyond the three classical MOR, KOR and DOR subtypes, the nociceptin opioid peptide receptor (NOP)

is actively pursued as a potential target for novel analgesic therapeutics (Zaveri, 2016); the widespread expression of NOP and its upregulation in chronic pain states suggest a potential role for NOP antagonists in pain therapy (Calo & Lambert, 2018; Zaveri, 2016). Indeed, molecules that combine a MOR and NOP partial agonist mode of action have been shown to provide antinociception in the absence of side effects in nonhuman primates (Ding, et al., 2018).

The paucity of novel opioid-based analgesics reaching the bedside reflects a general attrition in G protein-coupled receptors (GPCR) drug discovery programmes. Translation of candidate molecules from in vitro pharmacological characterisation into pre-clinical and clinical settings still represents a significant hurdle. Differences in experimental conditions, both in vitro and in animal models, are likely to underlie this translational challenge.

This review examines the preclinical animal models used to evaluate the key opioid-induced behaviours. We consider the influence of distinct variables in the experimental protocols, as well as the potential implications for differences in receptor reserve in each system. Finally, we discuss how the methods to assess opioid action in vivo and in vitro relate to each other in the context of bridging the translational gap in opioid drug discovery (Figure 1). In particular, we focus on the methods used to assess opioid-induced antinociception, respiratory depression, constipation, hyperalgesia and tolerance in the drug discovery setting. While the rewarding, addictive and consequent withdrawal effects associated with opioid use are major side effects, their complex and multi-faceted nature as well as the myriad of approaches used to investigate them are outside the scope of this review. The mechanisms underlying these behaviours, as well as the methods used to study them in preclinical models are elegantly reviewed elsewhere (Banks & Negus, 2017; Charbogne, Kieffer, & Befort, 2014; Kreek, et al., 2012; Negus & Moerke, 2019; Rodríguez-Arias, Aguilar, Manzanedo, & Miñarro, 2010; Sadee, Oberdick, & Wang, 2020; Swain, Gewirtz, & Harris, 2021)

2- Assessment of opioid-induced antinociception

Antinociception refers to the inhibition of the detection of a painful stimulus by nociceptive (pain) neurons. In contrast, the term analgesia is used when referring to the alleviation of the experience of pain, which includes not only the inhibition of nociceptive signalling but also a subjective component that cannot be assessed in animal models. As such, the term antinociception is used to indicate the reductions in pain state observed in nonhuman animals, where an assessment of the subjective component is not possible. The most widely used in vivo models of antinociception involve a pain stimulus (physical activation of nociceptive fibre) being delivered to the animal to elicit a pain behaviour and the subsequent measurement of the reduction of such pain behaviours by analgesic agents. Thermal nociception tests are commonly used in the discovery and characterisation of opioid compounds with the hot plate assay and tail flick (or tail withdrawal) tests being regularly used as the first in vivo measurement of antinociceptive efficacy (Table 1). Other mechanical (e.g. Von Frey, Hargreaves) and chemical (e.g. formalin, complete Freund's adjuvant) nociception assays are also used to evaluate antinociceptive efficacy of opioids in conditions such as inflammatory and neuropathic pain.

Tail flick assay. The tail flick assay measures the latency required for an animal to remove or flick its tail from a heat source. It is typically used in rodents that are usually restrained (by scruffing, cupping, wrapping, or placed in a tube) when a heat stimulus is applied to the distal portion of the tail (D'Amour & Smith, 1941; Hardy, 1953; Hardy, Stoll, Cunningham, Benson, & Greene, 1957; Hardy, Wolff, & Goodell, 1940). The noxious heat stimulus can be immersion of the tail in warm water or application of radiant heat to a smaller section of the tail with greater heat intensity (i.e. non radiant heat) resulting in shorter reaction times (Carroll, 1959; Carstens & Wilson, 1993; Granat & Saelens, 1973; Levine, Murphy, Seidenwurm, Cortez, & Fields, 1980). Baseline tail-flick latency is typically 2-4 seconds (Raffa, et al., 1992). Importantly, this assay measures the lower cervical reflex arc responsible for the tail flick. It therefore monitors the response to a spinal reflex, rather than an indication of pain behaviours involving higher brain centres.

Hot plate assay. The hot plate assay measures behaviours that require central processing and are considered to integrate supraspinal pathways. It consists of the application of a thermal stimulus to the paws, tail and the dorsal flank of the animal and measures the latency for the animal to elicit a pain behaviour (Eddy & Leimbach, 1953; Ocallaghan & Holtzman, 1975; Woolfe & Macdonald, 1944). Typically unrestrained rodents are placed in a metal surface maintained at a constant temperature and manifestations of pain are seen as fluttering of the feet, rearing and licking forepaws/hindpaws, squirming to dissipate heat, and jumping (Carter, 1991).

While both the tail flick and the hot plate assay provide useful information on the antinociceptive actions of opioids, there are obvious ethical considerations integral to the experiment that prevent unnecessary animal suffering, and yet ensure that the data remain valid and useable. Limits in the maximum temperature of the noxious stimulus (the thermal limit - typically 48-55°C) and maximum latency cut-offs (i.e maximum time until response is observed, typically 10-30 sec) prevent damage to the tissues of the experimental animal (Table 1). It is also important to note that increased temperatures are associated with not just decreased latencies (Carroll, 1959; Carstens & Wilson, 1993; Ren & Han, 1979) but also associated reduced antinociceptive efficacy, namely, analgesics are less efficacious the higher the temperature (Ankier, 1974; Hunskaar, Berge, & Hole, 1986; Zimet, Wynn, Ford, & Rudo, 1986). In addition, ethical considerations also limit the frequency at which the test can be repeated in the same animal. This usually implies that data is acquired in 15-30 min bins, which impacts the temporal resolution of the assay and can affect determinations of peak effects and of pharmacokinetic profiles.

The necessary cut-offs in antinociceptive assays have significant implications in estimations of in vivo agonist efficacy. Antinociception is calculated as a percentage of the maximum possible effect (%MPE) which is calculated as follows:

$$\%MPE = \frac{\text{test latency} - \text{control latency}}{\text{Max. latency} - \text{control latency}} \times 100$$

where “test latency” is the latency measured for the test drug, “control latency” is the baseline latency and “Max latency” is the upper temporal limit established to prevent tissue damage. It follows that when the latency measured for the test drug equals or exceeds the maximum latency cut-off, the test compound will display 100% MPE. Thus, detection of differences of opioid antinociceptive efficacy beyond a certain threshold will be prevented.

The above-mentioned cut-offs also have an impact on the determinations of antinociceptive potency, which in turn are important in the determination of therapeutic windows, where ED50s (the effective dose eliciting a 50% of the maximal response) between antinociception and other side effects are compared. Similarly, they should be taken into account when different efficacies are observed between measurements of antinociception and of other opioid-induced side effects. Thus, different temperatures and latency cut-offs being used can impact interpretations of effects across different studies (Table 1).

There is significant accumulated evidence that shows that inbred strains of mice can vary significantly in their nociceptive sensitivity (Table 2) (Homanics, Quinlan, & Firestone, 1999; Mogil, et al., 1996). Differences across strains have been generally observed with regards to the baseline latencies and the antinociceptive responses of classical opioids such as morphine (Crain & Shen, 2000; Kest, Hopkins, Palmese, Adler, & Mogil, 2002; Mogil & Wilson, 1997). While such differences can be related to the different pharmacokinetics of opioid drugs in different strains, this remains to be systematically investigated. Thus, when comparing reports of antinociceptive efficacy of novel opioid drugs as well as when designing new compound evaluation strategies, the choice of mouse strain should also be taken into account.

3- Assessment of opioid-induced respiratory depression

Opioid-induced respiratory depression is a significant, potentially lethal, adverse effect of opioid agonists. MOR is expressed throughout the respiratory network of the brainstem, and recent studies

have demonstrated a key role of MOR expressed in nuclei including; the preBötzinger complex (preBötC), Kölliker-Fuse (KF), post-inspiratory complex, ventral respiratory column and the retrotrapezoid/parafacial nucleus (Bachmutsky, Durand, et al., 2020; Ramirez, et al., 2021; Varga, Reid, Kieffer, & Levitt, 2020). The relative importance of each respiratory brain nuclei to respiratory rhythmogenesis as well as their role in the response to exogenous opioids is currently debated (Ramirez, et al., 2021). While it is clear that the preBötC is an important site of action for opioid depression of respiration (Bachmutsky, Wei, Kish, & Yackle, 2020; Ramirez, et al., 2021), reports suggest both, an essential and a non-essential role of the preBötC for breathing rhythmogenesis (Gaspard Montandon & Horner, 2014) (Lalley, Pilowsky, Forster, & Zuperku, 2014). Further investigation is required to elucidate the importance of each nuclei both in the persistent control of respiration as well as in the effect of opioids on respiration.

Due to its acute onset and relative ease of measurement, respiratory depression is one of the first adverse effects to be assessed in the characterisation of novel opioid agonists (Gillis, Gondin, et al., 2020; Gillis, Kliever, et al., 2020a; Hill, et al., 2018; Manglik, et al., 2016; Schmid, et al., 2017). Several non-invasive methods can be used to monitor respiration in rodents and determine respiratory parameters (for extended review of these methods see (Hoymann, 2007)).

Whole body plethysmography. In whole body plethysmography (WBP), freely moving animals are placed in a closed chamber and the pressure fluctuations that occur during the breathing cycle are recorded. A pressure transducer monitors the pressure differences between the experimental chamber of the plethysmograph where the animal is placed and a reference chamber. Both chambers have a regulated flow of room air or a controlled combination of gas and the system is calibrated with known air volume changes. The three primary parameters derived from this technique are tidal volume (TV), the volume of each breath; respiratory frequency, the number of breaths per minute (BPM); and minute volume (MV), the composite of breath volume and frequency (Hill, et al., 2016). It is important to consider all three parameters as changes in MV may be due to a decrease in either

BPM, TV or both. For example, fentanyl-like drugs are thought to induce a decrease in TV through a separate action of muscle stiffness not commonly seen in other opioids (Hill, Santhakumar, Dewey, Kelly, & Henderson, 2020) , which may contribute to their lethality.

As respiration can be altered by stressed and quiescent states, measurements of respiration in WBP systems need to minimise the effect of these variables. Stress can induce a heightened respiratory baseline, and therefore, changes in respiration may indirectly be assessing the anxiogenesis and anxiolytic effects of the compounds tested (Lynch, et al., 2019). Minimising stress can be achieved with sufficient habituation of the animal to the WBP chamber (ideally the day prior to the experiment) (Hill, et al., 2016). As animals are unrestrained in the WBP chamber, it is possible for them to curl up and either sleep or enter a quiescent state. This can often be detected in vehicle administered groups (e.g. saline) when a significant reduction in respiration is observed while the treatment is known to have no effect on respiration. This effect appears to be mitigated by using larger WBP chambers such as those in comprehensive lab animal monitoring systems (CLAMS) (Reilley, et al., 2010) which provide a greater area for normal locomotor behaviour.

Timing of experiments and housing conditions that maximise the activity of rodents can also help mitigate these confounds in smaller WBP chambers. These usually involve conducting measurements in the most active phases of the night cycle (Bains, et al., 2018) and housing the rodents on a reverse lit day-night cycle that allows experimentation during the night cycle of the animal, when they are naturally more active. Additionally, a mild hypercapnic stimulus can help maintain steady respiratory rates of mice without a significant induction of stress (as measured by corticosterone release (Hill, et al., 2016)) without apparent changes in the ability or sensitivity of opioids to induce respiratory depression (Hill, et al., 2018).

Head-out plethysmography. In contrast to WPB, head-out plethysmography restrains the experimental animal in a plethysmograph chamber supplied with a controlled flow of air (Hoymann, 2007) but leaves the head free through a sealed neck ring. As movement restraint is a significant

stressor (Lynch, et al., 2019), it is likely that the anxiolytic effect of opioids, in addition to their respiratory depressant effects, contribute significantly to the measurements using this approach. However, it may be the method of choice when additional more invasive methods are used for the study of lung and airway pathology.

Pulse-oximetry. Unlike plethysmography, pulse-oximetry does not measure the mechanical actions of breathing in rodents but instead measures changes in blood oxygen levels. A decrease in blood oxygen saturation is used as a proxy for respiratory depression. The non-invasiveness and non-stressful properties of this method are advantages for the use of this approach to characterise the respiratory depressant effects of opioids in rodents (DeWire, et al., 2013; Faouzi, Varga, & Majumdar, 2020; Schmid, et al., 2017). It is however unclear how the respiratory parameters obtained using pulse oximetry relate to those obtained with the more established systems of whole body plethysmography and head out plethysmography. As mentioned above, minute volume, tidal volume as well as breathing frequency can be altered to differing extents by different opioids (Hill, et al., 2020).

It is important to note that experimental assessments of respiratory depression do not have the same cut-offs as antinociception assays. This allows for estimates of efficacy and potency that are not subject to a defined maximal effect. Moreover, it allows the assessment of the respiratory depressant potential of all novel opioids at higher doses than those providing effective antinociception, which defines the therapeutic window. Assessing the potential to induce respiratory depression is of relevance as this side effect underlies most opioid-overdose fatalities in humans.

The impact of strain sensitivity on the respiratory depressant effects of opioids has recently been described (Table 2) (Bubier, et al., 2020; Young, et al., 2018). Of note, the reduced sensitivity of the 129Sv1J mouse line to opioidergic responses has been suggested to underlie the arrestin-3 knock-out data (Bubier, et al., 2020; Kliewer, et al., 2020).

4- Assessment of opioid-induced constipation

Opioid-induced constipation (OIC) is one of the most common side effects of opioid use in the clinic (McNicol, et al., 2003). Severe OIC has been reported in 40-95% of patients following the onset of a prescribed opioid regime (Pappagallo, 2001; Prichard & Bharucha, 2015; Swegle & Logemann, 2006), impacting the patient's quality of life, decreasing compliance and often resulting in heightened pain (Hjalte, Berggren, Bergendahl, & Hjortsberg, 2010; Katz, 2002; Trescot, et al., 2008).

Opioids act to inhibit acetylcholinergic neurons preventing the release of neurotransmitters and increasing longitudinal smooth muscle tone while decreasing propulsive activity (Brock, et al., 2012; Wood & Galligan, 2004). These effects are thought to be primarily mediated by the MOR as the effects are absent in MOR knock-out mice (Roy, Liu, & Loh, 1998). Importantly, both in animals and in humans, tolerance does not seem to develop within the GI tract actions of opioids, unlike antinociceptive tolerance, that requires increasing doses of opioids to provide the same level of analgesia (Müller-Lissner, et al., 2017; Prichard & Bharucha, 2015). This was first identified in dogs (Plant & Miller, 1926) and has since been replicated across different species (Ling, Paul, Simantov, & Pasternak, 1989; Matsumoto, et al., 2016;). Lack of tolerance to morphine-induced constipation has been shown from short (≤ 72 hr) (Ross, Gabra, Dewey, & Akbarali, 2008) to longer (up to 10 days) administration periods. The use of peripherally restricted opioid antagonists, such as methylnaltrexone (Anissian, et al., 2012; Bader, Durk, & Becker, 2013; Michna, et al., 2011) or combination therapies of oxycodone and naloxone can be used to effectively treat OIC whilst retaining pain relief (Lowenstein, et al., 2009; Simpson, et al., 2008). Pre-clinically, the most common methods to measure OIC are faecal boli accumulation and glass bead expulsion.

Faecal boli accumulation measures the overall production of faecal matter over time (typically 2-6h) following administration of opioids. This is usually done in under controlled feeding in order to measure food consumption against expulsion, and additionally a dye (e.g blue ink, charcoal) may be introduced into the diet to aid tracking of the bolus (Anand, et al., 2018).

The **glass bead expulsion assay** requires brief anaesthesia of the animal in order to insert a small glass bead into a defined distance in the colon (Matsumoto, et al., 2016). Following recovery from the anaesthetic, the time taken for the bead expulsion is measured. In this assay the opioid treatment can be administered before or after insertion of the glass bead. Whilst this assay is reliable and reproducible, it is limited in its assessment of overall gut activity, as it only measures colonic transit effects. Comparatively, the faecal boli accumulation assay measures the effect of opioid inhibition throughout the entire gut, does not require the use of anaesthetics and is less invasive. However, it must also be considered that opioids can induce tolerance to differing degrees in colonic versus small and large intestinal transit in rodents (Matsumoto, et al., 2016; Mori, et al., 2013). Given these differences, the use of both assays in parallel may provide valuable information into regional differences in OIC.

While the literature surrounding mouse strain differences in relation to OIC is sparse, a recent study compared two inbred mouse strains (A/J and C57BL/6J) and found that C57BL/6J mice were significantly more constipated following doses of morphine exceeding 40 mg/kg (Table 2)(Young, et al., 2018).

5- Assessment of opioid-induced hyperalgesia and antinociceptive tolerance

Chronic opioid use can lead to opioid-induced antinociceptive tolerance and hyperalgesia. Analgesic or antinociceptive tolerance corresponds to a progressive decrease of analgesia produced by a given opioid dose. This results in the need to increase the dose of opioids to provide a similar analgesic effect. Cellular and molecular mechanisms that underlie MOR regulation have been comprehensively reviewed (Williams, et al., 2013). Whilst some mechanisms of MOR regulation such as phosphorylation

(Doll, et al., 2011) and desensitisation (Bailey, et al., 2009) have been thoroughly studied, there are still significant gaps in our understanding of the molecular processes responsible for loss of MOR function after chronic exposure to opioids. In particular the role of arrestins, whilst clearly important in the development of opioid tolerance through MOR desensitisation, is still not fully understood (Bohn, Lefkowitz, & Caron, 2002; Kliewer, et al., 2019; Williams, et al., 2013).

Opioid induced hyperalgesia (OIH) is characterised by a paradoxical increase in pain perception following the onset of opioid medication (Lee, Silverman, Hansen, Patel, & Manchikanti, 2011; Roeckel, Le Coz, Gaveriaux-Ruff, & Simonin, 2016). While most opioid drugs appear to induce OIH regardless of their intrinsic efficacy and mechanism of action (Angst & Clark, 2006; Araldi, Ferrari, & Levine, 2018; Compton, Canamar, Hillhouse, & Ling, 2012), the molecular mechanisms underlying this state of nociceptive sensitisation are complex and still not fully understood. The most important proposed mechanisms for OIH have been reviewed elsewhere (Lee, et al., 2011; Roeckel, et al., 2016). These mechanisms involve the NMDA-glutamatergic system, transient receptor potential channels V1 and M8 (TRPV1 and TRPM8), and are influenced by several factors including genetic background and sex differences of experimental animals (Roeckel, et al., 2016).

Experimentally, OIH and antinociceptive tolerance are measured through antinociception assays upon chronic administration of opioids, either by repeated administration or through osmotic minipumps (Hill, et al., 2018; Hill, et al., 2016; Koblish, et al., 2017). The most common antinociception assays used in this context are thermal stimulation (hot plate and tail flick) for antinociceptive tolerance and OIH, and mechanical stimulation for OIH assessment only (Koblish, et al., 2017; D.-Y. Liang, et al., 2006; Roeckel, et al., 2016). These allow the detection of significant changes in opioid-induced responses, and baseline latencies differences of naïve versus chronically treated animals are readily observed (in particular for OIH). However, when assessing for hyperalgesia, higher temperatures or applied forces are an impediment to obtaining clear, meaningful data; the baseline nociceptive latency of the animal decreases as the thermal or physical intensity increases (Carroll, 1959; Carstens & Wilson, 1993; Ren

& Han, 1979), therefore the ability to detect a decrease in baseline threshold is also reduced at higher temperatures.

The same inherent ethical limitations apply for assessment of hyperalgesia and tolerance as they do for antinociception assays. Moreover, another limiting factor is the amplitude of the baseline nociceptive latency as an increase in the severity of the noxious stimulus will compromise the detection window even further upon the development of OIH (see above for the thermal example) (Jensen & Finnerup, 2014; Yalcin, Charlet, Freund-Mercier, Barrot, & Poisbeau, 2009). It is also of particular importance that multiple pain modalities are tested in the context of OIH as the development of OIH in patients is usually related to both chronic use of opioids as well as an underlying pain states (Burma, Leduc-Pessah, & Trang, 2017; Marrone, et al., 2017). Other modalities include mechanical stimulation of pain responses (e.g. Von Frey filaments) (Koblish, et al., 2017), that can be performed in conjunction with pro-inflammatory treatments (e.g. carrageenan or capsaicin injections) (Luo, et al., 2008; Yalcin, et al., 2009) as well as neuropathic models of pain (e.g. nerve ligation assays) (Chen, et al., 2020).

6- In vitro measurements of opioid pharmacology and their relationship with opioid-induced effects in vivo

The antinociceptive, respiratory and gastrointestinal effects of opioid therapeutics are mainly caused by the activation of the MOR (Bachmutsky, Durand, et al., 2020; Matthes, et al., 1996; Roy, et al., 1998; Varga, et al., 2020). The MOR signals predominantly through the activation of $G\alpha_{i/o}$ and $\beta\gamma$ proteins. MOR activation alters neurotransmitter release through presynaptic inhibition of voltage-gated calcium channels (VGCC) and inhibits neuronal activity through hyperpolarisation caused by post-synaptic activation of G protein-coupled inwardly rectifying potassium (GIRK) channels. Moreover, G protein activation by MOR also results in inhibition of adenylate cyclase, resulting in decreased levels

of the second messenger cAMP. As with most GPCRs, the G protein signalling of MORs is regulated by phosphorylation of intracellular domains, arrestin binding and internalisation. Numerous in vitro assays are available for the detection of MOR signalling and regulation in cell lines. These assays include sensors to monitor receptor, G protein and GIRK channel activation, measurements of cAMP levels, recruitment of GRK and arrestins and receptor internalisation (Table 3). However, with the exception of electrophysiological approaches (Birdsong & Williams, 2020), application of these approaches for the detection of MOR signalling in neuronal cultures remains slightly more challenging.

Despite the initial reports, recent evidence suggests that a clear separation of the signalling responsible for antinociceptive versus deleterious side effects of opioids is unlikely (Bachmutsky, Wei, Durand, & Yackle, 2021; Kliewer, et al., 2020; Kliewer, et al., 2019). Antinociception, respiratory depression and constipation are all mediated by G protein activation by MOR and retained in arrestin KO mice (Bachmutsky, et al., 2021; Benyamin, et al., 2008; A. E. Conibear & Kelly, 2019; Gillis, Kliewer, et al., 2020b; Kliewer, et al., 2019; Matthes, et al., 1996; G. Montandon, et al., 2016; Valentino & Volkow, 2018). However, this should not preclude the development of improved opioids that minimise adverse effects and provide wider therapeutic windows through other mechanisms or pharmacological properties different than biased agonism. For example, the role of ligand binding kinetics, as well as kinetic of effect has been proposed to underlie potential signalling differences among GPCR ligands (Klein Herenbrink, et al., 2016; van der Velden, Heitman, & Rosenkilde, 2020) although this does not seem to be the case for some novel opioids (Pedersen, et al., 2020).

It has also been proposed that low intrinsic efficacy may provide an alternative explanation to the improved therapeutic profiles (Azevedo Neto, et al., 2020; Benredjem, et al., 2019; Gillis, Gondin, et al., 2020; Kelly, 2013). This is supported by a recent study of clinically used opioids which found that intrinsic efficacy, rather than any G protein/ β -arrestin bias, predicted the rate of reported adverse events (Benredjem, et al., 2019), and by the actions of the opioid buprenorphine, an extremely low efficacy MOR agonist with a ceiling effect in respiratory depression and reduced overdose risk (Dahan,

et al., 2006; Walsh, Preston, Stitzer, Cone, & Bigelow, 1994). In this context, the response of partial agonists, compounds with low intrinsic efficacy, is very sensitive to the presence of receptor reserve (also known as spare receptors). As such, partial agonists will display robust responses in systems with high receptor reserve, whilst in systems with lower receptor reserve they will produce a partial maximum response even at full receptor occupancy. As receptor reserve is a property of the tissue and of the agonist (Buchwald, 2019; S. J. Hill, 2006), it therefore follows that the same drug may elicit full or partial responses depending on the tissue receptor reserve. Although difficult to prove experimentally, these differences may explain the effects of low efficacy opioids (A. E. Conibear & Kelly, 2019; Gillis, Sreenivasan, & Christie, 2020; Pineyro & Nagi, 2021; Rajendra Uprety, et al., 2021). The presence of receptor reserve in the responses of opioid agonists is a pharmacological concept that has been thoroughly explored in cultured cell lines (Carliss, et al., 2009; Kelly, 2013) and utilised in electrophysiology (Lowe & Bailey, 2015). This is commonly assessed using irreversible antagonists (such as β -funaltrexamine (Takemori, Larson, & Portoghese, 1981), β -chlornaltrexamine (Portoghese, Larson, Jiang, Takemori, & Caruso, 1978) or methacinnamox (Broadbear, et al., 2000)) or genetic strategies to decrease receptor levels (Mizoguchi, et al., 1999; Singleton, et al., 2021; Sora, et al., 2001).

As mentioned above, measurements of antinociceptive efficacy are limited by the imposed cut-offs. However, given that low efficacy agonists such as buprenorphine or oliceridine provide effective antinociception, it may be suggested that some receptor reserve is present in this system. Similarly, as tail flick and hot plate assays do not measure identical responses, differences in receptor reserve may also be relevant to consider. The relationship between tolerance and receptor reserve has received particular attention (Chavkin & Goldstein, 1984; Mjanger & Yaksh, 1991; Williams, et al., 2013). A recent study, investigated the effect of irreversible antagonism in vitro and of reduced receptor expression in MOR^{+/-} mice to interrogate the antinociceptive tolerance of oliceridine. Although a clear effect was observed in terms of ligand efficacy, oliceridine was still able to induce tolerance in mice expressing 50% less MOR than wild type (Singleton, et al., 2021).

Despite the potential to explain the different actions of opioids in different tissues, the impact of receptor reserve in the other physiological responses of opioids such as respiratory depression and constipation have not as yet been studied and compared with the effect of receptor reserve on antinociception. Future studies addressing the relevance of receptor reserve for the effects of opioids in vivo are likely to provide a much-needed framework of efficacy to drug discovery programs that may suggest some new strategies for the development of improved analgesics.

7- Concluding remarks

- The inherent limitations in the experimental design of antinociception assays can influence determinations of efficacy of opioid drugs. When characterising novel opioid agonists, consideration should be taken into how these limitations affect the data.
- Differential strain sensitivity to the effects of opioids (including the potential for differences in drug pharmacokinetics) needs to be thoroughly studied. This is not only important when comparing actions of opioids across laboratories, but also when considering the use of genetically modified mice.
- Adverse side effects limit the therapeutic potential of novel opioid analgesics. It is important that all opioidergic behaviours induced by novel agonists are assessed at doses above those providing effective antinociception in order to understand the liabilities and risks associated with deliberate or accidental abuse.
- Whilst early in vitro assessment of novel opioids provides valuable insight into their actions, these assays are limited in their ability to predict side effect liabilities. Early ex vivo characterisation of novel opioids in native tissue may provide better indications for side effect liability. Recent measurements of respiratory depression in zebra fish provides an example of an innovative higher throughput screen for novel opioids (Zaig, da Silveira Scarpellini, & Montandon, 2021).
- Further assessments of the impact of receptor reserve and relative receptor expression levels across different tissues and animal strains are necessary to understand the relationship between efficacy and opioid-induced responses in vivo and provide a framework for the development of new opioid-based analgesics.

Acknowledgments: This work was supported by the Academy of Medical Sciences. Figure 1 was made using Biorender (www.biorender.com). We would like to acknowledge the authors of studies that, due to space limitations, are not cited in this manuscript.

Conflict of Interest Statement: The authors declare no conflicts of interest

Figure 1 – Experimental considerations for the assessment of opioid pharmacology in vitro and in vivo. In vitro and in vivo characterisations of opioid action are both essential in drug discovery. However, important factors need to be considered to provide a consistent and systematic framework of opioid action. In vitro, compounds are tested for their binding to MOR, and for their ability to activate downstream signalling. These assays need to take into account distinct variables than can affect the measured outcome. In vivo, candidates are usually first assessed for their antinociceptive efficacy, and then for their ability to elicit adverse effects. OIC: Opioid-induced constipation, OIH: Opioid-induced hyperalgesia.

Compound	Antinociception assay - species	Strain	Temp & cut-off	Reference
TRV130	Hot plate – mouse	C57/BL6J	56°C, 30 sec	(DeWire, et al., 2013)
		C57/BL6	54°C, 20 sec	(Gillis, Gondin, et al., 2020)
		ICR	55°C, 30 sec	(Mori, et al., 2021)
	Tail flick – mouse	Swiss Webster	52°C, 10 sec	(Altarifi, et al., 2017)
		C57/BL6	variable, 10 sec	(D. Y. Liang, Li, Nwaneshiudu, Irvine, & Clark, 2019)
	Hot plate – rat	Sprague-Dawley	52°C, 30 sec	(DeWire, et al., 2013)
	Tail flick – rat	Sprague-Dawley	variable, 15 sec	
		Sprague-Dawley	50°C, 20 sec	(DeWire, et al., 2013) (Schwienteck, et al., 2019)
TRV0109101	Hot plate – mouse	C57/BL6	56°C, 30 sec	(Koblish, et al., 2017)
	Hot plate – rat	Sprague-Dawley	52°C, 30 sec	
	Tail flick – rat	Sprague-Dawley	variable, 15 sec	
	Von Frey filaments – mouse	C57/BL6	0.4g only	
PZM21	Hot plate – mouse	C57/BL6J	55°C, 30 sec	(Manglik, et al., 2016)
		C57/BL6J	52.5°C, 30 sec	(Kudla, et al., 2019)
		C57/BL6	54°C, 20 sec	(Gillis, Gondin, et al., 2020)
		CD-1	52.5°C, 30 sec	(Hill, et al., 2018)
	Tail flick – mouse	C57/BL6J	56°C, 10 sec	(Manglik, et al., 2016)
		C57/BL6J	variable, 9 sec	(Kudla, et al., 2019)

	Affective vs reflexive – hot plate – mouse	C57/BL6J	52.5°C, 30 sec	(Manglik, et al., 2016)
	Formalin chemical assay – mouse	C57/BL6J	1% formalin	(Manglik, et al., 2016)
SR-17018	Hot plate – mouse	C57/BL6J	52°C, 20 sec	(Grim, et al., 2020; Schmid, et al., 2017)
		C57/BL6	54°C, 20 sec	(Gillis, Gondin, et al., 2020)
	Tail flick – mouse	C57/BL6J	49°C, 30 sec	(Grim, et al., 2020; Schmid, et al., 2017)
Mitragynine	Tail flick – mouse	CD-1	variable, 3 x	(Varadi, et al., 2016)
		C57/BL6	baseline	
		C57/BL6J	variable, 3 x	(Wilson, et al., 2021)
		129S1	baseline	(Kruegel, et al., 2019)
			48°C, 30 sec variable, 10 sec	
7-OH	Tail flick – mouse	CD-1	variable, 3 x	(Varadi, et al., 2016)
Mitragynine		129S1	baseline variable, 10 sec	(Kruegel, et al., 2019)
Mitragynine Pseudoindoxyl	Hot plate – mouse	CD-1	55°C, 30 sec	(Varadi, et al., 2016)
	Tail flick – mouse	CD-1	variable, 3 x	(Varadi, et al., 2016)
		C57/BL6	baseline	
		129Sv6	variable, 3 x	
		C57/BL6J	baseline variable, 3 x baseline	(Wilson, et al., 2021)

			48°C, 30 sec	
Tianeptine	Hot plate – mouse	C57/BL6	50 or 55°C, 30 sec	(Samuels, et al., 2017)
MP-1208 & MP1207	Tail flick – mouse	C57BL/6	55°C, 15 sec	(R. Uprety, et al., 2021)
CYM51010	Tail flick – mouse	C57/BL6 C57/BL6 CD-1 129	Heat intensity 10 (IITC Life Science), 20 sec variable, 10 sec variable, 10 sec variable, 10 sec	(Gomes, et al., 2013) (Faouzi, et al., 2020)
MP135	Tail flick – mouse Hargreaves - rat	C57/BL6 CD-1 129 Long Evans	variable, 10 sec variable, 10 sec variable, 10 sec not given	(Faouzi, et al., 2020)
AT-201	Tail flick – mouse	ICR	Radial beam (Stoelting, Wood Day, IL), 15 sec	(Khroyan, et al., 2007; Toll, et al., 2009)
Endomorphin analogues	Tail flick – mouse Tail flick - rat	CD-1 Sprague-Dawley	Variable, 9 sec Variable, 9 sec	(Zadina, et al., 2016)

Table 1 – Opioid-induced antinociception assays used in MOR drug discovery. Summary of the antinociception assay, species, strain and cut-offs used for the evaluation of novel opioids.

Drug	Assay	Strains	Observations	References
Morphine	Hot water tail flick – 49°C and 15 sec cutoff Four day escalating dose of morphine (10-40 mg/kg) used to induce tolerance.	Strain – baseline (s) 129P3 – 2.4 ± 0.1 A – 2.4 ± 0.1 AKR – 2.9 ± 0.2 BALB/c – 3.1 ± 0.2 C3H/He – 1.8 ± 0.1 C57BL/6 – 2.2 ± 0.1 CBA – 1.9 ± 0.1 DBA/2 – 2.5 ± 0.1 LP – 2.8 ± 0.1 SJL – 2.2 ± 0.1 SWR – 1.8 ± 0.1	<ul style="list-style-type: none"> Significant differences in baseline latencies. Significant differences in the relative degree of tolerance (from 0.8 to 10.8 fold change in morphine ED₅₀ values (day 1 vs day 4)). 	Kest and Mogil, 2002
Morphine	Hot water tail flick – 55°C and 10 sec cutoff	Strain – baseline (s) SW – 2.7 ± 0.6 129/SvEv – 3.5 ± 0.6	<ul style="list-style-type: none"> Significant differences in baseline latencies. Differences in duration of antinociception (>6 hours in 129/SvEv vs 2 hours in SW). 129/SvEv mice were approx. 10-fold more sensitive to morphine 	Crain and Shen, 1999
Morphine	Hot water tail flick – 49°C and 15 sec cutoff	Strain – baseline (s) 129/J – 4.7 ± 0.2 129/SvJ – 4.5 ± 0.1 B6 – 2.6 ± 0.1	<ul style="list-style-type: none"> Significant differences in baseline latencies. Right shifted dose-response curve to cumulative morphine in B6 mice. 	Mogil et al., 1997
Morphine	LD ₅₀ determination by percent survival – measured by return to regular breathing	Strain and sex – LD₅₀ (mg/kg) 129S1/SvImJ F – 631.3 129S1/SvImJ M – 664.2 A/J F – 212.2 A/J M – 225.2 C57BL/6J F – 311.6 C57BL/6J M – 254.3 CAST/EiJ F – 882.2 CAST/EiJ M – 429.9 NOD/ShiLtJ F – 811.0 NOD/ShiLtJ M – 588.8 NZO/HILtJ F – 333.9 NZO/HILtJ M – 324.4 PWK/PhJ F – 261.0 PWK/PhJ M – 359.1 WSB/EiJ F – 526.4 WSB/EiJ M – 695.6	<ul style="list-style-type: none"> Baseline respiration data not reported. Significant differences in LD₅₀ values between strains and sex. 	Bubier et al., 2020
Morphine	Measurement of respiration (whole body plethysmography) and constipation (Charcoal transit)	C57BL/6J A/J	<ul style="list-style-type: none"> Baseline values not compared between strains. Enhanced sensitivity to morphine respiratory depression and significantly greater constipation in C57BL/6J mice vs A/J mice 	Young et al., 2018

Table 2 – Strain differences in opioid-induced behaviours. Summary of the assays, strains and results reported in the studies addressing strain differences to opioid sensitivity.

Compound	Response	Cell type	Considerations	References
TRV130 (Oliceridine)	β -arrestin recruitment	HEK293	DiscoverX PathHunter, BRET, FRET	DeWire et al 2013, Gillis et al 2020, Pedersen et al, Mori et al 2021, Ehrlich et al 2019, Yudin et al 2019
	Nb33 recruitment		BRET	
	mGsi recruitment		BRET	
	G protein activation		BRET, FRET	
	GIRK/VGC channel modulation		Membrane potential assay, patch-clamp electrophysiology	
	Inhibition of Fsk-induced cAMP accumulation		cAMP HiRange Kit, BRET, GloSensor	
	Internalisation		DiscoverX PathHunter BRET, TR-FRET, imaging	
TRV0109101	MOPr phosphorylation	HEK293	Western blot	(Koblish, et al., 2017)
	β -arrestin recruitment		DiscoverX PathHunter	
	Inhibition of Fsk-induced cAMP accumulation		cAMP HiRange Kit	
	Internalisation		DiscoverX PathHunter	
PZM21	MOPr phosphorylation	HEK293	pSer ³⁷⁵ Western blot	(Manglik, et al., 2016) (Gillis, Gondin, et al., 2020) (Hill, et al., 2018) Yudin et al 2019
	β -arrestin recruitment		DiscoverX PathHunter, BRET, FRET	
	Nb33 recruitment		BRET	
	mGsi recruitment		BRET	
	G protein activation		BRET, GTP γ S binding, FRET	
	GIRK/VGC channel modulation		Membrane potential assay, patch-clamp electrophysiology	
	Calcium release		FLIPR (Fluo-4 dye)	
	Inhibition of Fsk-induced cAMP accumulation		BRET, GloSensor	
	Internalisation		DiscoverX PathHunter BRET	
SR-17018	MOPr phosphorylation	CHO-K1, U2OS, HEK293	Western blot	(Grim, et al., 2020; Schmid, et al., 2017) (Gillis, Gondin, et al., 2020)
	β -arrestin recruitment		DiscoverX PathHunter, BRET, FRET, imaging	
	Nb33 recruitment		BRET	
	mGsi recruitment		BRET	

	G protein activation GIRK channel activation Inhibition of Fsk-induced cAMP accumulation Internalisation MOPr phosphorylation		BRET, GTP γ S binding Membrane potential assay BRET, cAMP HiRange Kit BRET, imaging Western blot	
Mitragynine	G protein activation β -arrestin recruitment	CHO	GTP γ S binding DiscoverX PathHunter	(Varadi, et al., 2016) (Wilson, et al., 2021)(Wilson, et al., 2021)(Wilson, et al., 2021)(Wilson, et al., 2021)(Wilson, et al., 2021)(Wilson, et al., 2021)
7-OH Mitragynine	G protein activation β -arrestin recruitment	CHO	GTP γ S binding DiscoverX PathHunter	(Varadi, et al., 2016)
Mitragynine Pseudoindoxyl	G protein activation β -arrestin recruitment	CHO	GTP γ S binding DiscoverX PathHunter	(Varadi, et al., 2016)
Tianeptine	G protein activation Inhibition of Fsk-induced cAMP accumulation	HEK293T	BRET BRET	Gassaway et al 2014
MP-1208 & MP1207	β -arrestin recruitment G protein activation Inhibition of Fsk-induced cAMP accumulation	HEK293, HTLA	Tango, BRET BRET, GTP γ S binding GloSensor	(R. Uprety, et al., 2021)
CYM51010	β -arrestin recruitment G protein activation	U2OS	DiscoverX PathHunter BRET, GTP γ S binding	(Gomes, et al., 2013) (Faouzi, et al., 2020)
MP135	β -arrestin recruitment G protein activation	U2OS	DiscoverX PathHunter BRET, GTP γ S binding	(Faouzi, et al., 2020)

Table 3 – In vitro signalling assays used in MOR drug discovery. Summary of the cell signalling assays commonly used for opioid drug discovery. Fsk; forskolin, ORs; opioid receptors, BRET: Bioluminescence Resonance Energy Transfer, FRET; Förster Resonance Energy Transfer, TR-FRET; Time-Resolve FRET; GIRK channel, G protein inwardly rectifying channel; VGCC, voltage-gated calcium channel.

8- References

- Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017). Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceadine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. *Journal of Psychopharmacology*, 31, 730-739.
- Anand, J. P., Kochan, K. E., Nastase, A. F., Montgomery, D., Griggs, N. W., Traynor, J. R., Mosberg, H. I., & Jutkiewicz, E. M. (2018). In vivo effects of μ -opioid receptor agonist/ δ -opioid receptor antagonist peptidomimetics following acute and repeated administration. *Br J Pharmacol*, 175, 2013-2027.
- Angst, M. S., & Clark, J. D. (2006). Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology*, 104, 570-587.
- Anissian, L., Schwartz, H. W., Vincent, K., Vincent, H. K., Carpenito, J., Stambler, N., & Ramakrishna, T. (2012). Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. *J Hosp Med*, 7, 67-72.
- Ankier, S. I. (1974). New hot plate tests to quantify antinociceptive and narcotic antagonist activities. *Eur J Pharmacol*, 27, 1-4.
- Araldi, D., Ferrari, L. F., & Levine, J. D. (2018). Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat. *Neuroscience*, 394, 60-71.
- Audet, N., Charfi, I., Mnie-Filali, O., Amraei, M., Chabot-Doré, A.-J., Millecamps, M., Stone, L. S., & Pineyro, G. (2012). Differential Association of Receptor-G $\beta\gamma$ Complexes with β -Arrestin2 Determines Recycling Bias and Potential for Tolerance of Delta Opioid Receptor Agonists. *The Journal of Neuroscience*, 32, 4827-4840.
- Azevedo Neto, J., Costanzini, A., De Giorgio, R., Lambert, D. G., Ruzza, C., & Calo, G. (2020). Biased versus Partial Agonism in the Search for Safer Opioid Analgesics. *Molecules*, 25.
- Bachmutsky, I., Durand, A., & Yackle, K. (2020). β 2-Arrestin germline knockout does not attenuate opioid respiratory depression. *bioRxiv*, 2020.2008.2028.272575.
- Bachmutsky, I., Wei, X. P., Durand, A., & Yackle, K. (2021). β 2-Arrestin germline knockout does not attenuate opioid respiratory depression. *Elife*, 10, e62552.
- Bachmutsky, I., Wei, X. P., Kish, E., & Yackle, K. (2020). Opioids depress breathing through two small brainstem sites. *Elife*, 9, e52694.
- Bader, S., Durk, T., & Becker, G. (2013). Methylnaltrexone for the treatment of opioid-induced constipation. *Expert Rev Gastroenterol Hepatol*, 7, 13-26.
- Bailey, C. P., Oldfield, S., Llorente, J., Caunt, C. J., Teschemacher, A. G., Roberts, L., McArdle, C. A., Smith, F. L., Dewey, W. L., Kelly, E., & Henderson, G. (2009). Involvement of PKC α and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. *Br J Pharmacol*, 158, 157-164.
- Bains, R. S., Wells, S., Sillito, R. R., Armstrong, J. D., Cater, H. L., Banks, G., & Nolan, P. M. (2018). Assessing mouse behaviour throughout the light/dark cycle using automated in-cage analysis tools. *Journal of Neuroscience Methods*, 300, 37-47.
- Banks, M. L., & Negus, S. S. (2017). Insights from Preclinical Choice Models on Treating Drug Addiction. *Trends Pharmacol Sci*, 38, 181-194.
- Bennett, D. L., Clark, A. J., Huang, J., Waxman, S. G., & Dib-Hajj, S. D. (2019). The Role of Voltage-Gated Sodium Channels in Pain Signaling. *Physiological Reviews*, 99, 1079-1151.

- Benredjem, B., Gallion, J., Pelletier, D., Dallaire, P., Charbonneau, J., Cawkill, D., Nagi, K., Gosink, M., Lukasheva, V., Jenkinson, S., Ren, Y., Somps, C., Murat, B., Van Der Westhuizen, E., Le Gouill, C., Lichtarge, O., Schmidt, A., Bouvier, M., & Pineyro, G. (2019). Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response. *Nature Communications*, *10*, 4075.
- Benyamin, R., Trescot, A. M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., Glaser, S. E., & Vallejo, R. (2008). Opioid complications and side effects. *Pain Physician*, *11*, S105-120.
- Birdsong, W. T., & Williams, J. T. (2020). Recent Progress in Opioid Research from an Electrophysiological Perspective. *Molecular Pharmacology*, *98*, 401-409.
- Bohn, L. M., Lefkowitz, R. J., & Caron, M. G. (2002). Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. *J Neurosci*, *22*, 10494-10500.
- Broadbear, J. H., Sumpter, T. L., Burke, T. F., Husbands, S. M., Lewis, J. W., Woods, J. H., & Traynor, J. R. (2000). Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. *J Pharmacol Exp Ther*, *294*, 933-940.
- Brock, C., Olesen, S. S., Olesen, A. E., Frokjaer, J. B., Andresen, T., & Drewes, A. M. (2012). Opioid-Induced Bowel Dysfunction Pathophysiology and Management. *Drugs*, *72*, 1847-1865.
- Broom, D. C., Jutkiewicz, E. M., Folk, J. E., Traynor, J. R., Rice, K. C., & Woods, J. H. (2002). Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. *Psychopharmacology (Berl)*, *164*, 42-48.
- Brust, T. F., Morgenweck, J., Kim, S. A., Rose, J. H., Locke, J. L., Schmid, C. L., Zhou, L., Stahl, E. L., Cameron, M. D., Scarry, S. M., Aube, J., Jones, S. R., Martin, T. J., & Bohn, L. M. (2017). A G Protein-Biased Ligand of the Kappa Opioid Receptor is Antinociceptive and Antipruritic But Does Not Cause Sedation or Dysphoria. *Faseb Journal*, *31*.
- Bubier, J. A., He, H., Philip, V. M., Roy, T., Hernandez, C. M., Bernat, R., Donohue, K. D., O'Hara, B. F., & Chesler, E. J. (2020). Genetic variation regulates opioid-induced respiratory depression in mice. *Sci Rep*, *10*, 14970.
- Buchwald, P. (2019). A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. *Frontiers in Pharmacology*, *10*.
- Burma, N. E., Leduc-Pessah, H., & Trang, T. (2017). Genetic deletion of microglial Panx1 attenuates morphine withdrawal, but not analgesic tolerance or hyperalgesia in mice. *Channels (Austin)*, *11*, 487-494.
- Calo, G., & Lambert, D. G. (2018). Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic. *Br J Anaesth*, *121*, 1105-1114.
- Camilleri, M. (2011). Opioid-Induced Constipation: Challenges and Therapeutic Opportunities. *American Journal of Gastroenterology*, *106*, 835-842.
- Carliss, R. D., Keefer, J. F., Perschke, S., Welch, S., Rich, T. C., & Weissman, A. D. (2009). Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers. *Pharmacol Biochem Behav*, *92*, 495-502.
- Carroll, M. N. (1959). THE EFFECT OF INJURY IN NOCICEPTIVE TESTS EMPLOYED IN ANALGETIC ASSAYS. *Archives Internationales De Pharmacodynamie Et De Therapie*, *123*, 48-57.
- Carstens, E., & Wilson, C. (1993). RAT TAIL-FLICK REFLEX - MAGNITUDE MEASUREMENT OF STIMULUS-RESPONSE FUNCTION, SUPPRESSION BY MORPHINE AND HABITUATION. *Journal of Neurophysiology*, *70*, 630-639.
- Carter, R. B. (1991). DIFFERENTIATING ANALGESIC AND NON-ANALGESIC DRUG ACTIVITIES ON RAT HOT PLATE - EFFECT OF BEHAVIORAL END-POINT. *Pain*, *47*, 211-220.
- Charbogne, P., Kieffer, B. L., & Befort, K. (2014). 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse. *Neuropharmacology*, *76 Pt B*, 204-217.

- Charfi, I., Audet, N., Bagheri Tudashki, H., & Pineyro, G. (2015). Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands. *Br J Pharmacol*, 172, 435-448.
- Chavkin, C., & Goldstein, A. (1984). Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus. *Proc Natl Acad Sci U S A*, 81, 7253-7257.
- Chavkin, C., & Koob, G. F. (2016). Dynorphin, Dysphoria, and Dependence: the Stress of Addiction. *Neuropsychopharmacology*, 41, 373-374.
- Chen, Y., Moutal, A., Navratilova, E., Kopruszinski, C., Yue, X., Ikegami, M., Chow, M., Kanazawa, I., Bellampalli, S. S., Xie, J., Patwardhan, A., Rice, K., Fields, H., Akopian, A., Neugebauer, V., Dodick, D., Khanna, R., & Porreca, F. (2020). The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. *Science Translational Medicine*, 12, eaay7550.
- Compton, P., Canamar, C. P., Hillhouse, M., & Ling, W. (2012). Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. *J Pain*, 13, 401-409.
- Conibear, A. E., Asghar, J., Hill, R., Henderson, G., Borbely, E., Tekus, V., Helyes, Z., Palandri, J., Bailey, C., Starke, I., von Mentzer, B., Kendall, D., & Kelly, E. (2020). A Novel G Protein-Biased Agonist at the δ Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain. *Journal of Pharmacology and Experimental Therapeutics*, 372, 224-236.
- Conibear, A. E., & Kelly, E. (2019). A Biased View of mu-Opioid Receptors? *Mol Pharmacol*, 96, 542-549.
- Crain, S. M., & Shen, K. (2000). Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions. *Brain Res*, 856, 227-235.
- Crombie, A., Arezzo, J., Cowan, C., DeWire, S., Gowen-MacDonald, W., Hawkins, M., Jutkiewicz, E., Kramer, M., Koblish, M., Lark, M., Liu, G., Miskowski, T., Nguyen, L., Pitis, P., Pradhan, A., Rominger, D., Schwartz, E., Yamashita, D., & Violin, J. (2015). TRV250: A novel biased ligand at the delta receptor for the potential treatment of migraine. *Cephalalgia*, 35, 1225-1226.
- D'Amour, F. E., & Smith, D. L. (1941). A method for determining loss of pain sensation. *Journal of Pharmacology and Experimental Therapeutics*, 72, 74-79.
- Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. *BJA: British Journal of Anaesthesia*, 96, 627-632.
- Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR. Morbidity and mortality weekly report*, 67, 1001-1006.
- Dekan, Z., Sianati, S., Yousuf, A., Sutcliffe, K. J., Gillis, A., Mallet, C., Singh, P., Jin, A. H., Wang, A. M., Mohammadi, S. A., Stewart, M., Ratnayake, R., Fontaine, F., Lacey, E., Piggott, A. M., Du, Y. P., Canals, M., Sessions, R. B., Kelly, E., Capon, R. J., Alewood, P. F., & Christie, M. J. (2019). A tetrapeptide class of biased analgesics from an Australian fungus targets the micro-opioid receptor. *Proc Natl Acad Sci U S A*, 116, 22353-22358.
- DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X. T., Pitis, P. M., Gotchev, D., Yuan, C., Koblish, M., Lark, M. W., & Violin, J. D. (2013). A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. *J Pharmacol Exp Ther*, 344, 708-717.
- Ding, H., Kiguchi, N., Yasuda, D., Daga, P. R., Polgar, W. E., Lu, J. J., Czoty, P. W., Kishioka, S., Zaveri, N. T., & Ko, M.-C. (2018). A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. *Science Translational Medicine*, 10, eaar3483.
- Doll, C., Konietzko, J., Poll, F., Koch, T., Holtt, V., & Schulz, S. (2011). Agonist-selective patterns of micro-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. *Br J Pharmacol*, 164, 298-307.

- Eddy, N. B., & Leimbach, D. (1953). SYNTHETIC ANALGESICS .2. DITHIENYLBUTENYLAMINES AND DITHIENYLBUTYLAMINES. *Journal of Pharmacology and Experimental Therapeutics*, 107, 385-393.
- Faouzi, A., Varga, B. R., & Majumdar, S. (2020). Biased Opioid Ligands. *Molecules*, 25, 4257.
- Gassaway, M. M., Rives, M. L., Kruegel, A. C., Javitch, J. A., & Sames, D. (2014). The atypical antidepressant and neurorestorative agent tianeptine is a μ -opioid receptor agonist. *Transl Psychiatry*, 4, e411.
- Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., Katte, T. A., Reekie, T., Grimsey, N. L., Kassiou, M., Kellam, B., Krasel, C., Halls, M. L., Connor, M., Lane, J. R., Schulz, S., Christie, M. J., & Canals, M. (2020). Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. *Sci Signal*, 13.
- Gillis, A., Kliewer, A., Kelly, E., Henderson, G., Christie, M. J., Schulz, S., & Canals, M. (2020a). Critical Assessment of G Protein-Biased Agonism at the μ -Opioid Receptor. *Trends Pharmacol Sci*.
- Gillis, A., Kliewer, A., Kelly, E., Henderson, G., Christie, M. J., Schulz, S., & Canals, M. (2020b). Critical Assessment of G Protein-Biased Agonism at the μ -Opioid Receptor. *Trends Pharmacol Sci*, 41, 947-959.
- Gillis, A., Sreenivasan, V., & Christie, M. J. (2020). Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window. *Mol Pharmacol*, 98, 410-424.
- Gomes, I., Fujita, W., Gupta, A., Saldanha, S. A., Negri, A., Pinello, C. E., Eberhart, C., Roberts, E., Filizola, M., Hodder, P., & Devi, L. A. (2013). Identification of a μ - δ opioid receptor heteromer-biased agonist with antinociceptive activity. *Proc Natl Acad Sci U S A*, 110, 12072-12077.
- Granat, F. R., & Saelens, J. K. (1973). EFFECT OF STIMULUS INTENSITY ON POTENCY OF SOME ANALGETIC AGENTS. *Archives Internationales De Pharmacodynamie Et De Therapie*, 205, 52-60.
- Grim, T. W., Schmid, C. L., Stahl, E. L., Pantouli, F., Ho, J. H., Acevedo-Canabal, A., Kennedy, N. M., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2020). A G protein signaling-biased agonist at the μ -opioid receptor reverses morphine tolerance while preventing morphine withdrawal. *Neuropsychopharmacology*, 45, 416-425.
- Haouzi, P., McCANN, M., & TUBBS, N. (2021). Respiratory effects of low and high doses of fentanyl in control and β -arrestin 2 deficient mice. *Journal of Neurophysiology*, 0, null.
- Hardy, J. D. (1953). THRESHOLDS OF PAIN AND REFLEX CONTRACTION AS RELATED TO NOXIOUS STIMULATION. *Journal of Applied Physiology*, 5, 725-739.
- Hardy, J. D., Stoll, A. M., Cunningham, D., Benson, W. M., & Greene, L. (1957). RESPONSES OF THE RAT TO THERMAL RADIATION. *American Journal of Physiology*, 189, 1-5.
- Hardy, J. D., Wolff, H. G., & Goodell, H. (1940). Studies on pain. A new method for measuring pain threshold: Observations on spatial summation of pain. *Journal of Clinical Investigation*, 19, 649-657.
- Hedegaard H, M. A., Warner M. . (2017). Drug overdose deaths in the United States, 1999–2018. *Hyattsville, MD: National Center for Health Statistics., NCHS Data Brief, no 356*
- Hill, R., Disney, A., Conibear, A., Sutcliffe, K., Dewey, W., Husbands, S., Bailey, C., Kelly, E., & Henderson, G. (2018). The novel μ -opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. *Br J Pharmacol*, 175, 2653-2661.
- Hill, R., Lyndon, A., Withey, S., Roberts, J., Kershaw, Y., MacLachlan, J., Lingford-Hughes, A., Kelly, E., Bailey, C., Hickman, M., & Henderson, G. (2016). Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine. *Neuropsychopharmacology*.
- Hill, R., Santhakumar, R., Dewey, W., Kelly, E., & Henderson, G. (2020). Fentanyl depression of respiration: Comparison with heroin and morphine. *British Journal of Pharmacology*, 177, 254-265.

- Hill, S. J. (2006). G-protein-coupled receptors: past, present and future. *Br J Pharmacol*, 147 Suppl 1, S27-37.
- Hjalte, F., Berggren, A.-C., Bergendahl, H., & Hjortsberg, C. (2010). The Direct and Indirect Costs of Opioid-Induced Constipation. *Journal of Pain and Symptom Management*, 40, 696-703.
- Homanics, G. E., Quinlan, J. J., & Firestone, L. L. (1999). Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. *Pharmacol Biochem Behav*, 63, 21-26.
- Hoymann, H. G. (2007). Invasive and noninvasive lung function measurements in rodents. *J Pharmacol Toxicol Methods*, 55, 16-26.
- Hunskar, S., Berge, O. G., & Hole, K. (1986). A modified hot-plate test sensitive to mild analgesics. *Behav Brain Res*, 21, 101-108.
- Jensen, T. S., & Finnerup, N. B. (2014). Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. *The Lancet Neurology*, 13, 924-935.
- Katz, N. (2002). The impact of pain management on quality of life. *Journal of Pain and Symptom Management*, 24, S38-S47.
- Kelly, E. (2013). Ligand bias at the μ -opioid receptor. *Biochem Soc Trans*, 41, 218-224.
- Kest, B., Hopkins, E., Palmese, C. A., Adler, M., & Mogil, J. S. (2002). Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. *Pharmacol Biochem Behav*, 73, 821-828.
- Khroyan, T. V., Zaveri, N. T., Polgar, W. E., Orduna, J., Olsen, C., Jiang, F., & Toll, L. (2007). SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/ μ -opioid receptor partial agonist: analgesic and rewarding properties in mice. *J Pharmacol Exp Ther*, 320, 934-943.
- Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., Javitch, J. A., Christopoulos, A., & Lane, J. R. (2016). The role of kinetic context in apparent biased agonism at GPCRs. *Nat Commun*, 7, 10842.
- Kliwer, A., Gillis, A., Hill, R., Schmiedel, F., Bailey, C., Kelly, E., Henderson, G., Christie, M. J., & Schulz, S. (2020). Morphine-induced respiratory depression is independent of beta-arrestin2 signalling. *Br J Pharmacol*, 177, 2923-2931.
- Kliwer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J. T., Levitt, E. S., Williams, J. T., Christie, M. J., & Schulz, S. (2019). Phosphorylation-deficient G-protein-biased μ -opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. *Nat Commun*, 10, 367.
- Koblish, M., Carr, R., Siuda, E. R., Rominger, D. H., Gowen-MacDonald, W., Cowan, C. L., Crombie, A. L., Violin, J. D., & Lark, M. W. (2017). TRV0109101, a G Protein-Biased Agonist of the μ -Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration. *Journal of Pharmacology and Experimental Therapeutics*, 362, 254-262.
- Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., & Butelman, E. R. (2012). Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. *J Clin Invest*, 122, 3387-3393.
- Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., Majumdar, S., & Sames, D. (2019). 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. *ACS Cent Sci*, 5, 992-1001.
- Kudla, L., Bugno, R., Skupio, U., Wiktorowska, L., Solecki, W., Wojtas, A., Golembiowska, K., Zádor, F., Benyhe, S., Buda, S., Makuch, W., Przewlocka, B., Bojarski, A. J., & Przewlocki, R. (2019). Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine. *British Journal of Pharmacology*, 176, 4434-4445.
- Lalley, P. M., Pilowsky, P. M., Forster, H. V., & Zuperku, E. J. (2014). CrossTalk opposing view: The pre-Botzinger complex is not essential for respiratory depression following systemic administration of opioid analgesics. *Journal of Physiology-London*, 592, 1163-1166.

- Lee, M., Silverman, S. M., Hansen, H., Patel, V. B., & Manchikanti, L. (2011). A comprehensive review of opioid-induced hyperalgesia. *Pain Physician*, 14, 145-161.
- Levine, J. D., Murphy, D. T., Seidenwurm, D., Cortez, A., & Fields, H. L. (1980). A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY PRODUCED BY OPIATE ANALGESICS. *Brain Research*, 201, 129-141.
- Liang, D.-Y., Liao, G., Wang, J., Usuka, J., Guo, Y., Peltz, G., & Clark, J. D. (2006). A Genetic Analysis of Opioid-induced Hyperalgesia in Mice. *Anesthesiology*, 104, 1054-1062.
- Liang, D. Y., Li, W. W., Nwaneshiudu, C., Irvine, K. A., & Clark, J. D. (2019). Pharmacological Characters of Oliceridine, a μ -Opioid Receptor G-Protein-Biased Ligand in Mice. *Anesth Analg*, 129, 1414-1421.
- Ling, G. S., Paul, D., Simantov, R., & Pasternak, G. W. (1989). Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. *Life Sci*, 45, 1627-1636.
- Lovell, K. M., Frankowski, K. J., Stahl, E. L., Slauson, S. R., Yoo, E., Prisinzano, T. E., Aube, J., & Bohn, L. M. (2017). Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over beta Arrestin2 Signaling Bias (vol 6, pg 1411, 2015). *Acs Chemical Neuroscience*, 8, 1628-1628.
- Lowe, J. D., & Bailey, C. P. (2015). Functional selectivity and time-dependence of μ -opioid receptor desensitization at nerve terminals in the mouse ventral tegmental area. *British Journal of Pharmacology*, 172, 469-481.
- Lowenstein, O., Leyendecker, P., Hopp, M., Schutter, U., Rogers, P. D., Uhl, R., Bond, S., Kremers, W., Nichols, T., Krain, B., & Reimer, K. (2009). Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. *Expert Opin Pharmacother*, 10, 531-543.
- Luo, F., Yang, C., Chen, Y., Shukla, P., Tang, L., Wang, L. X., & Wang, Z. J. (2008). Reversal of chronic inflammatory pain by acute inhibition of Ca^{2+} /calmodulin-dependent protein kinase II. *J Pharmacol Exp Ther*, 325, 267-275.
- Lynch, J. J., 3rd, Rossignol, E., Moehrle, J. J., Van Vleet, T. R., Marsh, K. C., Parman, T., Mirsalis, J., Ottinger, S. E., Segreti, J. A., Rao, M., & Mittelstadt, S. W. (2019). Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats. *J Pharmacol Toxicol Methods*, 99, 106580.
- Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hubner, H., Huang, X. P., Sassano, M. F., Giguere, P. M., Lober, S., Da, D., Scherrer, G., Kobilka, B. K., Gmeiner, P., Roth, B. L., & Shoichet, B. K. (2016). Structure-based discovery of opioid analgesics with reduced side effects. *Nature*, 537, 185-190.
- Marrone, G. F., Le Rouzic, V., Varadi, A., Xu, J., Rajadhyaksha, A. M., Majumdar, S., Pan, Y. X., & Pasternak, G. W. (2017). Genetic dissociation of morphine analgesia from hyperalgesia in mice. *Psychopharmacology (Berl)*, 234, 1891-1900.
- Matsumoto, K., Umemoto, H., Mori, T., Akatsu, R., Saito, S., Tashima, K., Shibasaki, M., Kato, S., Suzuki, T., & Horie, S. (2016). Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ -opioid receptors in mice. *Eur J Pharmacol*, 771, 220-228.
- Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dolle, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature*, 383, 819-823.
- McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett, K., Gialeli-Goudas, M., Chew, P. W., Lau, J., & Carr, D. (2003). Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *Journal of Pain*, 4, 231-256.

- Michna, E., Blonsky, E. R., Schulman, S., Tzanis, E., Manley, A., Zhang, H., Iyer, S., & Randazzo, B. (2011). Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. *J Pain*, 12, 554-562.
- Mizoguchi, H., Narita, M., Oji, D. E., Suganuma, C., Nagase, H., Sora, I., Uhl, G. R., Cheng, E. Y., & Tseng, L. F. (1999). The mu-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in mu-opioid receptor knockout mice. *Neuroscience*, 94, 203-207.
- Mjanger, E., & Yaksh, T. L. (1991). Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. *J Pharmacol Exp Ther*, 258, 544-550.
- Mogil, J. S., Sternberg, W. F., Marek, P., Sadowski, B., Belknap, J. K., & Liebeskind, J. C. (1996). The genetics of pain and pain inhibition. *Proc Natl Acad Sci U S A*, 93, 3048-3055.
- Mogil, J. S., & Wilson, S. G. (1997). Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. *Eur J Pain*, 1, 293-297.
- Montandon, G., & Horner, R. (2014). CrossTalk proposal: The preBötzinger complex is essential for the respiratory depression following systemic administration of opioid analgesics. *The Journal of Physiology*, 592, 1159-1162.
- Montandon, G., Ren, J., Victoria, N. C., Liu, H., Wickman, K., Greer, J. J., & Horner, R. L. (2016). G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids. *Anesthesiology*, 124, 641-650.
- Mores, K. L., Cummins, B. R., Cassell, R. J., & van Rijn, R. M. (2019). A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists. *Frontiers in Pharmacology*, 10.
- Mori, T., Shibasaki, Y., Matsumoto, K., Shibasaki, M., Hasegawa, M., Wang, E., Masukawa, D., Yoshizawa, K., Horie, S., & Suzuki, T. (2013). Mechanisms that underlie μ -opioid receptor agonist-induced constipation: differential involvement of μ -opioid receptor sites and responsible regions. *J Pharmacol Exp Ther*, 347, 91-99.
- Mori, T., Takemura, Y., Arima, T., Iwase, Y., Narita, M., Miyano, K., Hamada, Y., Suda, Y., Matsuzawa, A., Sugita, K., Matsumura, S., Sasaki, S., Yamauchi, T., Higashiyama, K., Uezono, Y., Yamazaki, M., Kuzumaki, N., & Narita, M. (2021). Further investigation of the rapid-onset and short-duration action of the G protein-biased μ -ligand oliceridine. *Biochem Biophys Res Commun*, 534, 988-994.
- Müller-Lissner, S., Bassotti, G., Coffin, B., Drewes, A. M., Breivik, H., Eisenberg, E., Emmanuel, A., Laroche, F., Meissner, W., & Morlion, B. (2017). Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. *Pain Med*, 18, 1837-1863.
- Negus, S. S., & Moerke, M. J. (2019). Determinants of opioid abuse potential: Insights using intracranial self-stimulation. *Peptides*, 112, 23-31.
- Ocallaghan, J. P., & Holtzman, S. G. (1975). QUANTIFICATION OF ANALGESIC ACTIVITY OF NARCOTIC-ANTAGONISTS BY A MODIFIED HOT-PLATE PROCEDURE. *Journal of Pharmacology and Experimental Therapeutics*, 192, 497-505.
- Office of National Statistics, U. (2019). <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2018registrations>.
- Okie, S. (2010). A flood of opioids, a rising tide of deaths. *N Engl J Med*, 363, 1981-1985.
- Panchal, S. J., Mueller-Schwefe, P., & Wurzelmann, J. I. (2007). Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. *International Journal of Clinical Practice*, 61, 1181-1187.
- Pappagallo, M. (2001). Incidence, prevalence, and management of opioid bowel dysfunction. *American Journal of Surgery*, 182, 11S-18S.

- Pedersen, M. F., Wróbel, T. M., Märcher-Rørsted, E., Pedersen, D. S., Møller, T. C., Gabriele, F., Pedersen, H., Matosiuk, D., Foster, S. R., Bouvier, M., & Bräuner-Osborne, H. (2020). Biased agonism of clinically approved μ -opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. *Neuropharmacology*, 166, 107718.
- Pineyro, G., & Nagi, K. (2021). Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β -arrestin/G protein signaling bias. *Cellular Signalling*, 80, 109906.
- Plant, O. H., & Miller, G. H. (1926). EFFECTS OF MORPHINE AND SOME OTHER OPIUM ALKALOIDS ON THE MUSCULAR ACTIVITY OF THE ALIMENTARY CANAL I. ACTION ON THE SMALL INTESTINE IN UNANESTHETIZED DOGS AND MAN. *Journal of Pharmacology and Experimental Therapeutics*, 27, 361.
- Portoghese, P. S., Larson, D. L., Jiang, J. B., Takemori, A. E., & Caruso, T. P. (1978). 6beta-[N,N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan(chlornaltrexamine) a potent opioid receptor alkylating agent with ultralong narcotic antagonist activity. *J Med Chem*, 21, 598-599.
- Pradhan, A. A., Befort, K., Nozaki, C., Gavériaux-Ruff, C., & Kieffer, B. L. (2011). The delta opioid receptor: an evolving target for the treatment of brain disorders. *Trends Pharmacol Sci*, 32, 581-590.
- Pradhan, A. A. A., Walwyn, W., Nozaki, C., Filliol, D., Erbs, E., Matifas, A., Evans, C., & Kieffer, B. L. (2010). Ligand-Directed Trafficking of the δ -Opioid Receptor *In Vivo*: Two Paths Toward Analgesic Tolerance. *The Journal of Neuroscience*, 30, 16459-16468.
- Prichard, D., & Bharucha, A. (2015). Management of opioid-induced constipation for people in palliative care. *International Journal of Palliative Nursing*, 21, 272-280.
- Raehal, K. M., Walker, J. K., & Bohn, L. M. (2005). Morphine side effects in beta-arrestin 2 knockout mice. *J Pharmacol Exp Ther*, 314, 1195-1201.
- Raffa, R. B., Friderichs, E., Reimann, W., Shank, R. P., Codd, E. E., & Vaught, J. L. (1992). OPIOID AND NONOPIOID COMPONENTS INDEPENDENTLY CONTRIBUTE TO THE MECHANISM OF ACTION OF TRAMADOL, AN ATYPICAL OPIOID ANALGESIC. *Journal of Pharmacology and Experimental Therapeutics*, 260, 275-285.
- Ramirez, J. M., Burgraff, N. J., Wei, A. D., Baertsch, N. A., Varga, A. G., Baghdoyan, H. A., Lydic, R., Morris, K. F., Bolser, D. C., & Levitt, E. S. (2021). Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding. *J Neurophysiol*, 125, 1899-1919.
- Reilley, K. J., Giulianotti, M., Dooley, C. T., Nefzi, A., McLaughlin, J. P., & Houghten, R. A. (2010). Identification of two novel, potent, low-liability antinociceptive compounds from the direct in vivo screening of a large mixture-based combinatorial library. *AAPS J*, 12, 318-329.
- Ren, M. F., & Han, J. S. (1979). RAT TAIL FLICK ACUPUNCTURE ANALGESIA MODEL. *Chinese Medical Journal*, 92, 576-582.
- Rodríguez-Arias, M., Aguilar, M. A., Manzanedo, C., & Miñarro, J. (2010). Preclinical evidence of new opioid modulators for the treatment of addiction. *Expert Opin Investig Drugs*, 19, 977-994.
- Roeckel, L. A., Le Coz, G. M., Gavériaux-Ruff, C., & Simonin, F. (2016). Opioid-induced hyperalgesia: Cellular and molecular mechanisms. *Neuroscience*, 338, 160-182.
- Ross, G. R., Gabra, B. H., Dewey, W. L., & Akbarali, H. I. (2008). Morphine tolerance in the mouse ileum and colon. *J Pharmacol Exp Ther*, 327, 561-572.
- Roy, S., Liu, H. C., & Loh, H. H. (1998). μ -Opioid receptor-knockout mice: the role of μ -opioid receptor in gastrointestinal transit. *Molecular Brain Research*, 56, 281-283.
- Sá, K. N., Moreira, L., Baptista, A. F., Yeng, L. T., Teixeira, M. J., Galhardoni, R., & de Andrade, D. C. (2019). Prevalence of chronic pain in developing countries: systematic review and meta-analysis. *Pain reports*, 4, e779-e779.
- Sadee, W., Oberdick, J., & Wang, Z. (2020). Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management. *Molecules*, 25.

- Samuels, B. A., Nautiyal, K. M., Kruegel, A. C., Levinstein, M. R., Magalong, V. M., Gassaway, M. M., Grinnell, S. G., Han, J., Ansonoff, M. A., Pintar, J. E., Javitch, J. A., Sames, D., & Hen, R. (2017). The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. *Neuropsychopharmacology*, *42*, 2052-2063.
- Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017). Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. *Cell*, *171*, 1165-1175 e1113.
- Schwientek, K. L., Faunce, K. E., Rice, K. C., Obeng, S., Zhang, Y., Blough, B. E., Grim, T. W., Negus, S. S., & Banks, M. L. (2019). Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. *Neuropharmacology*, *150*, 200-209.
- Simpson, K., Leyendecker, P., Hopp, M., Muller-Lissner, S., Lowenstein, O., De Andres, J., Troy Ferrarons, J., Bosse, B., Krain, B., Nichols, T., Kremers, W., & Reimer, K. (2008). Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. *Curr Med Res Opin*, *24*, 3503-3512.
- Singleton, S., Baptista-Hon, D. T., Edelsten, E., McCaughey, K. S., Camplisson, E., & Hales, T. G. (2021). TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available μ -opioid receptor number. *British Journal of Pharmacology*, *178*, 1855-1868.
- Sora, I., Elmer, G., Funada, M., Pieper, J., Li, X. F., Hall, F. S., & Uhl, G. R. (2001). Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. *Neuropsychopharmacology*, *25*, 41-54.
- Swain, Y., Gewirtz, J. C., & Harris, A. C. (2021). Behavioral predictors of individual differences in opioid addiction vulnerability as measured using i.v. self-administration in rats. *Drug Alcohol Depend*, *221*, 108561.
- Swegle, J. M., & Logemann, C. (2006). Management of common opioid-induced adverse effects. *Am Fam Physician*, *74*, 1347-1354.
- Takemori, A. E., Larson, D. L., & Portoghese, P. S. (1981). The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. *Eur J Pharmacol*, *70*, 445-451.
- Tan-No, K., Nijima, F., Nakagawasai, O., Sato, T., Satoh, S., & Tadano, T. (2003). Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. *Eur J Pharm Sci*, *20*, 357-363.
- Toll, L., Khroyan, T. V., Polgar, W. E., Jiang, F., Olsen, C., & Zaveri, N. T. (2009). Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. *J Pharmacol Exp Ther*, *331*, 954-964.
- Trescot, A., Glaser, S. E., Hansen, H., Benyamin, R., Patel, S., & Manchikanti, L. (2008). Effectiveness of Opioids in the Treatment of Chronic Non-Cancer Pain. *Pain Physician*, *11*, S181-S200.
- Uprety, R., Che, T., Zaidi, S. A., Grinnell, S. G., Varga, B. R., Faouzi, A., Slocum, S. T., Allaoa, A., Varadi, A., Nelson, M., Bernhard, S. M., Kulko, E., Le Rouzic, V., Eans, S. O., Simons, C. A., Hunkele, A., Subrath, J., Pan, Y. X., Javitch, J. A., McLaughlin, J. P., Roth, B. L., Pasternak, G. W., Katritch, V., & Majumdar, S. (2021). Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. *Elife*, *10*.
- Uprety, R., Che, T., Zaidi, S. A., Grinnell, S. G., Varga, B. R., Faouzi, A., Slocum, S. T., Allaoa, A., Varadi, A., Nelson, M., Bernhard, S. M., Kulko, E., Le Rouzic, V., Eans, S. O., Simons, C. A., Hunkele, A., Subrath, J., Pan, Y. X., Javitch, J. A., McLaughlin, J. P., Roth, B. L., Pasternak, G. W., Katritch, V., & Majumdar, S. (2021). Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. *Elife*, *10*, e56519.

- Valentino, R. J., & Volkow, N. D. (2018). Untangling the complexity of opioid receptor function. *Neuropsychopharmacology*, 43, 2514-2520.
- van der Velden, W. J. C., Heitman, L. H., & Rosenkilde, M. M. (2020). Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors. *ACS Pharmacol Transl Sci*, 3, 179-189.
- Varadi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabo, M. R., Le Rouzic, V., Grinnell, S. G., Subrath, J. J., Warner, E., Kalra, S., Hunkele, A., Pagirsky, J., Eans, S. O., Medina, J. M., Xu, J., Pan, Y. X., Borics, A., Pasternak, G. W., McLaughlin, J. P., & Majumdar, S. (2016). Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit beta-Arrestin-2. *Journal of Medicinal Chemistry*, 59, 8381-8397.
- Varga, A. G., Reid, B. T., Kieffer, B. L., & Levitt, E. S. (2020). Differential impact of two critical respiratory centres in opioid-induced respiratory depression in awake mice. *The Journal of Physiology*, 598, 189-205.
- Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018). Cannabinoids and Pain: New Insights From Old Molecules. *Front Pharmacol*, 9, 1259.
- Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. *Clin Pharmacol Ther*, 55, 569-580.
- Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013). Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. *Pharmacol Rev*, 65, 223-254.
- Wilson, L. L., Chakraborty, S., Eans, S. O., Cirino, T. J., Stacy, H. M., Simons, C. A., Uprety, R., Majumdar, S., & McLaughlin, J. P. (2021). Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal. *Cell Mol Neurobiol*.
- Wood, J. D., & Galligan, J. J. (2004). Function of opioids in the enteric nervous system. *Neurogastroenterology and Motility*, 16, 17-28.
- Woolfe, G., & Macdonald, A. D. (1944). The evaluation of the analgesic action of Pethidine hydrochloride (Demerol). *Journal of Pharmacology and Experimental Therapeutics*, 80, 300-307.
- Yaksh, T. L., Woller, S. A., Ramachandran, R., & Sorkin, L. S. (2015). The search for novel analgesics: targets and mechanisms. *F1000Prime Rep*, 7, 56.
- Yalcin, I., Charlet, A., Freund-Mercier, M. J., Barrot, M., & Poisbeau, P. (2009). Differentiating thermal allodynia and hyperalgesia using dynamic hot and cold plate in rodents. *J Pain*, 10, 767-773.
- Young, A., Viswanath, A., Kalladka, M., Khan, J., Eliav, E., & Diehl, S. R. (2018). Mouse model demonstrates strain differences in susceptibility to opioid side effects. *Neurosci Lett*, 675, 110-115.
- Zadina, J. E., Nilges, M. R., Morgenweck, J., Zhang, X., Hackler, L., & Fasold, M. B. (2016). Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine. *Neuropharmacology*, 105, 215-227.
- Zaig, S., da Silveira Scarpellini, C., & Montandon, G. (2021). Respiratory depression and analgesia by opioid drugs in freely-behaving larval zebrafish. *Elife*, 10.
- Zaveri, N. T. (2016). Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. *J Med Chem*, 59, 7011-7028.
- Zimet, P. O., Wynn, R. L., Ford, R. D., & Rudo, F. G. (1986). Effect of hot plate temperature on the antinociceptive activity of mixed opioid agonist-antagonist compounds. *Drug Development Research*, 7, 277-280.